argenx

Foundation date

04/09/2009

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan.

Upcoming events

Latest news

  • Company growth prompts Connected-Pathology relocation to larger laboratory facilities to accommodate increase in study capacity

    22 hours ago

  • Japan welcomes companies, startups and knowledge institutions from Flanders

    Friday December 2nd 2022

  • FIT stimulates market diversification with renewed subsidy

    Thursday December 1st 2022

Jobs by argenx